ECSP099572A - Anticuerpos monoclonales anti-cxcl13 - Google Patents

Anticuerpos monoclonales anti-cxcl13

Info

Publication number
ECSP099572A
ECSP099572A EC2009009572A ECSP099572A ECSP099572A EC SP099572 A ECSP099572 A EC SP099572A EC 2009009572 A EC2009009572 A EC 2009009572A EC SP099572 A ECSP099572 A EC SP099572A EC SP099572 A ECSP099572 A EC SP099572A
Authority
EC
Ecuador
Prior art keywords
monoclonal antibodies
cxcl13
cxcl13 monoclonal
binding members
disorders
Prior art date
Application number
EC2009009572A
Other languages
English (en)
Inventor
Wendy Barker
Feenagh Anne Keyes
Original Assignee
Astrazeneca Ab
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Medimmune Ltd filed Critical Astrazeneca Ab
Publication of ECSP099572A publication Critical patent/ECSP099572A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)

Abstract

La presente invención se relaciona con los miembros de unión, especialmente con las moléculas de anticuerpos para CXCL13. Los miembros de unión son útiles para el tratamiento de los trastornos asociados con CXCL13, incluyendo los trastornos artíticos tal como la artritis reumatoide
EC2009009572A 2007-02-21 2009-08-12 Anticuerpos monoclonales anti-cxcl13 ECSP099572A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89088807P 2007-02-21 2007-02-21
US90804107P 2007-03-26 2007-03-26

Publications (1)

Publication Number Publication Date
ECSP099572A true ECSP099572A (es) 2009-10-30

Family

ID=39409730

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009572A ECSP099572A (es) 2007-02-21 2009-08-12 Anticuerpos monoclonales anti-cxcl13

Country Status (16)

Country Link
US (2) US20080199481A1 (es)
EP (1) EP2129691A1 (es)
JP (1) JP2010519280A (es)
KR (1) KR20090114464A (es)
CN (1) CN101636413A (es)
AR (1) AR065433A1 (es)
AU (1) AU2008217581A1 (es)
BR (1) BRPI0807631A2 (es)
CA (1) CA2677878A1 (es)
EC (1) ECSP099572A (es)
IL (1) IL200168A0 (es)
MX (1) MX2009008608A (es)
PE (1) PE20090161A1 (es)
TW (1) TW200846369A (es)
UY (1) UY30932A1 (es)
WO (1) WO2008102123A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102597268B (zh) * 2009-09-03 2017-09-22 弗·哈夫曼-拉罗切有限公司 用于治疗、诊断和监控类风湿性关节炎的方法
JP6097690B2 (ja) * 2010-09-02 2017-03-15 ヴァクシネックス， インコーポレイテッド 抗ｃｘｃｌ１３抗体およびそれを用いる方法
CN106177930A (zh) * 2010-12-14 2016-12-07 吉安特科技股份有限公司 抗cxcl13抗体和抗cxcr5抗体在恶性肿瘤的治疗或检测中的用途
CN102221607B (zh) * 2011-03-29 2013-10-02 浙江大学医学院附属第一医院 一种抗体组合物及其应用
FI2734552T3 (fi) 2011-07-22 2025-02-12 Csl Behring Gmbh Monoklonaaliset anti-tekijä xii/xiia -vasta-aineet ja niiden käyttö
KR102090969B1 (ko) * 2012-03-02 2020-03-19 백시넥스 인코포레이티드 Ｂ 세포-매개 염증 질환의 치료 방법
CN104870012A (zh) * 2012-06-27 2015-08-26 吉安特科技公司 用于炎性疾病的抗-cxcl9、抗-cxcl10、抗-cxcl11、抗-cxcl13、抗-cxcr3和抗-cxcr5试剂
US9790271B2 (en) 2013-01-31 2017-10-17 Vaccinex, Inc. Methods for increasing immunoglobulin A levels
JP6531893B2 (ja) * 2014-12-11 2019-06-19 国立大学法人 東京大学 濾胞性ヘルパーｔ細胞増加剤
CN104569431B (zh) * 2015-01-04 2017-01-11 深圳市艾瑞生物科技有限公司 一种快速定量检测肌钙蛋白i的均相荧光免疫试剂组及其制备方法
CN104569409B (zh) * 2015-01-04 2017-01-11 深圳市艾瑞生物科技有限公司 一种快速定量检测髓过氧化物酶的均相荧光免疫试剂组及其制备方法
CN104569374B (zh) * 2015-01-04 2017-01-11 深圳市艾瑞生物科技有限公司 一种快速定量检测c‑反应蛋白的均相荧光免疫试剂组及其制备方法
BR112020010753A2 (pt) * 2017-12-01 2020-11-24 The Regents Of The University Of California anticorpos anti-cxcr5 e composições e usos dos mesmos
MX2021002605A (es) * 2018-09-18 2021-07-21 I Mab Biopharma Us Ltd Anticuerpos anti-cxcl13 para el tratamiento de enfermedades autoinmunes y cancer.
US20220334132A1 (en) * 2019-08-08 2022-10-20 The Trustees Of Indiana University Methods for identifying and treating urinary tract infections
EP4164745A1 (en) 2020-06-11 2023-04-19 Vaccinex, Inc. Use of cxcl13 binding molecules to promote peripheral nerve regeneration
CN112521499B (zh) * 2020-12-24 2022-10-25 四川大学 抗cxcl13抗体及其用途
JP2024505718A (ja) * 2021-02-08 2024-02-07 ガルデルマ ホールディング エスエー ざ瘡の治療に使用するための遺伝子発現の低減方法
WO2023042314A1 (ja) * 2021-09-15 2023-03-23 和幸 吉崎 免疫異常性炎症性疾患を治療または予防するための組成物
WO2025171397A1 (en) * 2024-02-08 2025-08-14 Rose Diagnostics Inc. Methods to stabilize chemokine proteins in solution and for point of care detection of stabilized chemokine proteins

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5872215A (en) * 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
US5633149A (en) 1994-12-07 1997-05-27 Incyte Pharmaceuticals, Inc. Polynucleotide encoding novel chemokine expressed in inflamed adenoid
WO1996024668A1 (en) 1995-02-08 1996-08-15 Human Genome Sciences, Inc. Human chemokine beta-11 and human chemokine alpha-1
KR19990022283A (ko) 1995-06-05 1999-03-25 벤슨 로버트 에이치. 인체 케모킨 베타-11 및 인체 케모킨 알파-1
WO1998014477A1 (en) 1996-10-04 1998-04-09 Human Genome Sciences, Inc. THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING DISEASE STATES WITH LEUKOCYTE ADHESION INHIBITOR-1 (LAI-1), AND CHEMOKINE BETA-11 (Ckβ-11)
US6110695A (en) 1997-12-02 2000-08-29 The Regents Of The University Of California Modulating the interaction of the chemokine, B Lymphocyte Hemoattractant, and its Receptor, BLR1
CA2501422C (en) * 2004-04-29 2014-08-12 University Of Rochester Lymphoid chemokines in the diagnosis, monitoring and treatment of autoimmune disease
EP1703282A1 (en) 2005-03-15 2006-09-20 BRD, vertreten durch das BM für Gesundheit und Soziale Sicherung, Letztvertreten durch den Präsidenten des Robert-Koch-Inst. Method for ante mortem diagnosis of a TSE disease
GB0607774D0 (en) * 2006-04-20 2006-05-31 Renovo Group Plc Medicaments
WO2007124414A2 (en) * 2006-04-21 2007-11-01 Centocor, Inc. Cxcl13 antagonists and their use for the treatment of inflammatory diseases

Also Published As

Publication number Publication date
BRPI0807631A2 (pt) 2014-06-03
IL200168A0 (en) 2010-04-15
US8182811B2 (en) 2012-05-22
JP2010519280A (ja) 2010-06-03
CN101636413A (zh) 2010-01-27
MX2009008608A (es) 2009-09-16
EP2129691A1 (en) 2009-12-09
AR065433A1 (es) 2009-06-10
AU2008217581A1 (en) 2008-08-28
US20080199481A1 (en) 2008-08-21
KR20090114464A (ko) 2009-11-03
TW200846369A (en) 2008-12-01
CA2677878A1 (en) 2008-08-28
UY30932A1 (es) 2009-01-30
PE20090161A1 (es) 2009-04-30
WO2008102123A1 (en) 2008-08-28
US20100086942A1 (en) 2010-04-08

Similar Documents

Publication Publication Date Title
ECSP099572A (es) Anticuerpos monoclonales anti-cxcl13
AR061568A1 (es) Compuestos
MX391041B (es) Proteinas que contienen fc de anticuerpos heterodimericos y metodos para produccion de las mismas.
EA201300819A1 (ru) Молекулы антител, которые связываются с il-17a и il-17f
ECSP14013220A (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
CR20140029A (es) Proteínas de unión a antígeno de tnf-alfa con unión a fcrn incrementada
MX2009006471A (es) Anticuerpo anti especifico de linfopoyetina estromal timica de diseño.
CL2017000954A1 (es) Moléculas de unión a antígeno biespecificas activadoras de células t
EA201391389A1 (ru) Кристаллы антител против склеростина и составы на их основе
MX2013003182A (es) Purificacion de anticuerpos por cromatografia de lecho movil simulada.
CO2018004930A2 (es) Moléculas de unión específicas para asct2
CL2013001213A1 (es) Anticuerpo para interleuquina 17 (il-17); uso de este para tratar artritis reumatoide.
DOP2011000333A (es) Inmunoglobulina con dominio variable dual y usos de la mismas
SG178886A1 (en) Humanized anti-cdcp1 antibodies
DK2824183T3 (da) Fremgangsmåde til fremstilling af bispecifikke antistoffer
CO6571881A2 (es) Nuevos anticuerpos anti-cxcr4 humanizados para el tratamiento del cáncer
MX394214B (es) Sintesis de gamma-carbolinas fusionadas con heterociclo substituido.
MX375439B (es) Moleculas de union cd37 y sus inmunoconjugados.
CR9253A (es) Fijacion de la dosificacion de anticuerpos her
DOP2010000368A (es) Inmunoglobulinas con dominio variable dual y usos de la misma
EA200900492A1 (ru) Молекулы антител, которые связываются с il-17a и il-17f
ATE554105T1 (de) Veränderte antikörper
UY32501A (es) Anticuerpo antagonista específico para el heterodímero alfa4-beta7
CO6531489A2 (es) Anticuerpo anti -tslp modificado por técnicas de ingenieria genética
DK201100184U1 (da) Method for immunizing an avian species